In another example, the MTA-cooperative PRMT5 inhibitor, MRTX1719, demonstrates significant inhibitory effects on cancer cells with MTAP deletions by selectively binding to the PRMT5/MTA complex. This evidence concerns the gene PRMT5 and cancer.